Globus Medical, Inc. (NYSE:GMED) is one of the cheap robotics stocks to buy right now.
On May 18, Citizens reiterated a Market Perform rating on Globus Medical (NYSE:GMED) on first-quarter results exceeding expectations
The impressive results were characterized by 27% overall revenue growth and record earnings. Organic revenue was up 13%, driven by share gains and procedural volume strength in core spine. Consequently, worldwide revenues totaled $759.9 million, as base business net sales excluding Nevro totaled $677.2 million.
Robust revenue growth came as Globus Medical’s Musculoskeletal Solutions and Enabling Tech segments achieved broad-based growth in the quarter. Revenue in the Spine channel was up 10%, marking the third consecutive quarter of 10% growth. Net income in the quarter totaled $124.3 million as diluted earnings per share increased 64.7% to $1.12.